What's Going On With the Dip in Viking Therapeutics Stock?
Viking Therapeutics Inc. (NASDAQ: VKTX ) shares are dropping Tuesday amid a broader risk-off session, even though the stock’s longer-term uptrend and its sector’s strength both remain intact. Viking Therapeutics shares are sliding. Why is VKTX stock dropping? VKTX’s Chart Cools Off Within a Still-Bullish Sector Today’s decline may be to a broader pullback in risk appetite rather than anything specific to Viking, as the Nasdaq slips 0.63% and the S&P 500 sheds 0.45%. Viking’s stock has slipped below its short-term trend markers, running about 10% under its 20-day average and roughly 13.5% under its 50-day mark, with the retreat extending to nearly 10% under its 200-day average as well. Momentum readings echo that caution, with the MACD sitting beneath its signal line and a negative histogram. Still, the broader uptrend hasn’t been dismantled: the 50-day remains above the 200-day, keeping the golden cross formed back in July intact. Traders are watching $35 as resistance and $30 as support, a level that could invite base-building if buyers defend it. Viking operates within Healthcare, which ranks third among all 11 S&P sectors today and has climbed more than 11% over the past 90 days
Viking Therapeutics Inc. (NASDAQ: VKTX ) shares are dropping Tuesday amid a broader risk-off session, even though the stock’s longer-term uptrend and its sector’s strength both remain intact. Viking Therapeutics shares are sliding. Why is VKTX stock dropping?
45%. 5% under its 50-day mark, with the retreat extending to nearly 10% under its 200-day average as well. Momentum readings echo that caution, with the MACD sitting beneath its signal line and a negative histogram. Still, the broader uptrend hasn’t been dismantled: the 50-day remains above the 200-day, keeping the golden cross formed back in July intact.
Traders are watching $35 as resistance and $30 as support, a level that could invite base-building if buyers defend it. Viking operates within Healthcare, which ranks third among all 11 S&P sectors today and has climbed more than 11% over the past 90 days, giving the stock a supportive backdrop many of today’s weaker sectors don’t have. Viking’s Obesity Pipeline Continues to Build Momentum The bigger story for Viking remains its obesity pipeline, detailed Monday at the Morgan Stanley Global Healthcare Conference. com reported.
Management said it doesn’t need to dominate the obesity market, betting the category eventually splits between injectable and oral options, and pointed to VK3019, an earlier-stage amylin drug showing promising early results. Viking also said it has locked down sizable manufacturing capacity, including more than 100 million units each of vials, syringes and auto-injectors plus a billion tablets, positioning it to scale quickly if trials succeed. 90 at the time of publication on Tuesday, according to Pro. Read Also: 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today Image: Shutterstock